Diabetic neuropathy: One disease or two?

Brian C. Callaghan, Junguk Hur, Eva L. Feldman

Research output: Contribution to journalReview article

82 Citations (Scopus)

Abstract

Purpose of Review: To compare and contrast the evidence for the effect of glucose control on the prevention of neuropathy in type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). Recent Findings: In T1DM, multiple clinical trials have demonstrated a large benefit from enhanced glucose control, whereas the benefit in T2DM is much more modest. Epidemiologic and laboratory evidence exists to support factors other than hyperglycemia in the development of neuropathy including obesity, hypertension, dyslipidemia, inflammation, and insulin resistance. Summary: T1DM neuropathy and T2DM neuropathy are fundamentally different. In T1DM, glucose control has a large effect on the prevention of neuropathy; therefore, future efforts should continue to concentrate on this avenue of treatment. In contrast, in T2DM, glucose control has a small effect on the prevention of neuropathy; as a result, more research is needed to define the underlying mechanisms for the development of neuropathy. Understanding these mechanisms may lead to novel therapeutic approaches to prevent or treat diabetic neuropathy.

Original languageEnglish (US)
Pages (from-to)536-541
Number of pages6
JournalCurrent Opinion in Neurology
Volume25
Issue number5
DOIs
StatePublished - Oct 1 2012

Fingerprint

Diabetic Neuropathies
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Glucose
Dyslipidemias
Hyperglycemia
Insulin Resistance
Obesity
Clinical Trials
Hypertension
Inflammation
Research
Therapeutics

Keywords

  • metabolic syndrome
  • neuropathy
  • type 1 diabetes
  • type 2 diabetes

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Diabetic neuropathy : One disease or two? / Callaghan, Brian C.; Hur, Junguk; Feldman, Eva L.

In: Current Opinion in Neurology, Vol. 25, No. 5, 01.10.2012, p. 536-541.

Research output: Contribution to journalReview article

Callaghan, Brian C. ; Hur, Junguk ; Feldman, Eva L. / Diabetic neuropathy : One disease or two?. In: Current Opinion in Neurology. 2012 ; Vol. 25, No. 5. pp. 536-541.
@article{2726539d7ac5440f8b9b5d12f91f97cb,
title = "Diabetic neuropathy: One disease or two?",
abstract = "Purpose of Review: To compare and contrast the evidence for the effect of glucose control on the prevention of neuropathy in type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). Recent Findings: In T1DM, multiple clinical trials have demonstrated a large benefit from enhanced glucose control, whereas the benefit in T2DM is much more modest. Epidemiologic and laboratory evidence exists to support factors other than hyperglycemia in the development of neuropathy including obesity, hypertension, dyslipidemia, inflammation, and insulin resistance. Summary: T1DM neuropathy and T2DM neuropathy are fundamentally different. In T1DM, glucose control has a large effect on the prevention of neuropathy; therefore, future efforts should continue to concentrate on this avenue of treatment. In contrast, in T2DM, glucose control has a small effect on the prevention of neuropathy; as a result, more research is needed to define the underlying mechanisms for the development of neuropathy. Understanding these mechanisms may lead to novel therapeutic approaches to prevent or treat diabetic neuropathy.",
keywords = "metabolic syndrome, neuropathy, type 1 diabetes, type 2 diabetes",
author = "Callaghan, {Brian C.} and Junguk Hur and Feldman, {Eva L.}",
year = "2012",
month = "10",
day = "1",
doi = "10.1097/WCO.0b013e328357a797",
language = "English (US)",
volume = "25",
pages = "536--541",
journal = "Current Opinion in Neurology",
issn = "1350-7540",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Diabetic neuropathy

T2 - One disease or two?

AU - Callaghan, Brian C.

AU - Hur, Junguk

AU - Feldman, Eva L.

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Purpose of Review: To compare and contrast the evidence for the effect of glucose control on the prevention of neuropathy in type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). Recent Findings: In T1DM, multiple clinical trials have demonstrated a large benefit from enhanced glucose control, whereas the benefit in T2DM is much more modest. Epidemiologic and laboratory evidence exists to support factors other than hyperglycemia in the development of neuropathy including obesity, hypertension, dyslipidemia, inflammation, and insulin resistance. Summary: T1DM neuropathy and T2DM neuropathy are fundamentally different. In T1DM, glucose control has a large effect on the prevention of neuropathy; therefore, future efforts should continue to concentrate on this avenue of treatment. In contrast, in T2DM, glucose control has a small effect on the prevention of neuropathy; as a result, more research is needed to define the underlying mechanisms for the development of neuropathy. Understanding these mechanisms may lead to novel therapeutic approaches to prevent or treat diabetic neuropathy.

AB - Purpose of Review: To compare and contrast the evidence for the effect of glucose control on the prevention of neuropathy in type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). Recent Findings: In T1DM, multiple clinical trials have demonstrated a large benefit from enhanced glucose control, whereas the benefit in T2DM is much more modest. Epidemiologic and laboratory evidence exists to support factors other than hyperglycemia in the development of neuropathy including obesity, hypertension, dyslipidemia, inflammation, and insulin resistance. Summary: T1DM neuropathy and T2DM neuropathy are fundamentally different. In T1DM, glucose control has a large effect on the prevention of neuropathy; therefore, future efforts should continue to concentrate on this avenue of treatment. In contrast, in T2DM, glucose control has a small effect on the prevention of neuropathy; as a result, more research is needed to define the underlying mechanisms for the development of neuropathy. Understanding these mechanisms may lead to novel therapeutic approaches to prevent or treat diabetic neuropathy.

KW - metabolic syndrome

KW - neuropathy

KW - type 1 diabetes

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84866332807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866332807&partnerID=8YFLogxK

U2 - 10.1097/WCO.0b013e328357a797

DO - 10.1097/WCO.0b013e328357a797

M3 - Review article

C2 - 22892951

AN - SCOPUS:84866332807

VL - 25

SP - 536

EP - 541

JO - Current Opinion in Neurology

JF - Current Opinion in Neurology

SN - 1350-7540

IS - 5

ER -